114 related articles for article (PubMed ID: 22088626)
1. Re: Pathological Stage Review is Indicated in Primary pT1 Bladder Cancer.
Wood DP
J Urol; 2011 Feb; 185(2):468. PubMed ID: 22088626
[No Abstract] [Full Text] [Related]
2. Pathological stage review is indicated in primary pT1 bladder cancer.
van Rhijn BW; van der Kwast TH; Kakiashvili DM; Fleshner NE; van der Aa MN; Alkhateeb S; Bangma CH; Jewett MA; Zlotta AR
BJU Int; 2010 Jul; 106(2):206-11. PubMed ID: 20002439
[TBL] [Abstract][Full Text] [Related]
3. T1G3 bladder cancer and Bacillus Calmette-Guérin: tell me something we don't know.
Yates DR
Eur Urol; 2015 Jan; 67(1):83-84. PubMed ID: 25109573
[No Abstract] [Full Text] [Related]
4. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
5. Words of wisdom. Re: prognostic factors and risk groups in T1G3 non–muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.
Lotan Y
Eur Urol; 2014 Nov; 66(5):968-9. PubMed ID: 25763447
[No Abstract] [Full Text] [Related]
6. Re: Paolo Gontero, Richard Sylvester, Francesca Pisano, et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol 2015;67:74-82.
Montorsi F; Gandaglia G
Eur Urol; 2015 Jan; 67(1):e7. PubMed ID: 25224572
[No Abstract] [Full Text] [Related]
7. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
Haase RN; Harving N
Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
[No Abstract] [Full Text] [Related]
8. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
9. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
10. A plea for long-term surveillance in bacillus Calmette-Guérin-treated non-muscle-invasive bladder cancer.
Meijer RP; van Rhijn BW
Eur Urol; 2012 Mar; 61(3):508-9. PubMed ID: 22154727
[No Abstract] [Full Text] [Related]
11. Tumor associated macrophages: predicting bacillus Calmette-Guerin immunotherapy outcomes.
Brandau S
J Urol; 2009 Apr; 181(4):1532-3. PubMed ID: 19230928
[No Abstract] [Full Text] [Related]
12. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
13. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
14. [International Consensus Panel--treatment strategies for superficial bladder cancer].
Adler S; St Niclas M
Aktuelle Urol; 2006 Sep; 37(5):320-3; discussion 322-3. PubMed ID: 17004179
[No Abstract] [Full Text] [Related]
15. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
Zieger K; Jensen KM
Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636
[TBL] [Abstract][Full Text] [Related]
16. Editorial comment.
Kamat AM
J Urol; 2009 Nov; 182(5):2203. PubMed ID: 19758663
[No Abstract] [Full Text] [Related]
17. The impact of the global bacille Calmette-Guérin shortage on treatment patterns: population-based data.
Perera M; Papa N; Christidis D; McGrath S; Manning T; Roberts M; Bolton D; Lawrentschuk N; Sengupta S
BJU Int; 2018 Feb; 121(2):169-172. PubMed ID: 29072817
[No Abstract] [Full Text] [Related]
18. [Immunotherapy in superficial bladder carcinoma].
Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
[TBL] [Abstract][Full Text] [Related]
19. BCG and bladder cancer.
Gilling PJ
N Z Med J; 2010 Nov; 123(1325):8-9. PubMed ID: 21317955
[No Abstract] [Full Text] [Related]
20. The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ.
Gaya JM; Palou J; Algaba F; Arce J; Rodríguez-Faba O; Villavicencio H
Can J Urol; 2010 Oct; 17(5):5370-6. PubMed ID: 20974029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]